Peptides Are Everywhere. What the FDA Moves Mean for Skin Care
FDA moves on injectable peptides do not touch your serums, dermatologists say. Here is what is actually changing, what is risky, and which topical products carry real clinical data.
Updated
The takeaway
- An FDA advisory committee recommended six restricted peptides in July 2026; the vote is a recommendation only, not approval.
- Topical peptides in skin care are regulated as cosmetics under cosmetics law and are not affected by the compounding restrictions.
- Copper peptide GHK-Cu is scheduled for FDA review by the end of February 2027, and Melanotan II is slated for review in early 2027.
Peptides reached peak popularity at the exact moment U.S. regulators started rewriting the rules on them. This past summer, the U.S. Department of Health and Human Services moved to reclassify usage and distribution restrictions for a batch of peptides. The motion is still in progress, and only a handful of the 18 peptides presented await FDA approval. Confusion about which peptides are safe has grown alongside the hype.
Dr. Mona Foad, a board-certified dermatologist and founder of MONA Dermatology, attributes the surge in interest to the GLP-1 boom. "Medications like Ozempic made 'peptide' a household word almost overnight, and suddenly consumers wanted to know what else peptides could do," she tells ELLE. "Add biohacking culture, social media, and this year's very public regulatory headlines, and you have a perfect storm."
Foad says the science has also improved. Formulations are more stable, delivery systems are smarter, and copper peptides in particular have exploded on social media because consumers see real results. She also points to a broader shift toward gentler anti-aging: "Patients want results without the irritation that comes with retinoids, and peptides deliver exactly that. The bottom line is that peptides aren't a trend; they're a proven category that finally has the spotlight it deserves."
What the new FDA regulations actually cover
The loosened rules apply only to injectable peptide products from compounding pharmacies—not the peptides in serums and creams, explains Dr. Corinne Erickson, MD, FAAD, MSCP, a board-certified dermatologist and Menopause Society Certified Practitioner. "The FDA has been going back and forth on which injectable peptides compounding pharmacies should be permitted to formulate, and the landscape has shifted from more restrictive back in 2023 to potentially less so as of July 2026," Erickson explains to ELLE.
Foad gives the timeline. "In 2023, the FDA restricted 19 peptides over safety concerns. This year, the government signaled it would ease many of those restrictions, and in July [2026], an FDA advisory committee recommended six of them. That vote is only a recommendation, not FDA approval, and it doesn't mean these peptides are proven safe or effective," she tells ELLE.
Topical skin care is largely unaffected
Both dermatologists agree the recommendation barely touches peptides approved for use in skin care. A peptide in a cream counts as a cosmetic ingredient, not a pharmaceutical one. "These are governed by cosmetics law, which now requires facility registration, product listing, safety substantiation, and adverse event reporting, but not FDA approval," Erickson says. The compounding debate is about what a pharmacy can put in a syringe, not what goes in a moisturizer.
One beauty-related peptide to watch is copper peptide, or GHK-Cu, which Foad says is scheduled for review by the end of February 2027. "The bottom line is that your topical peptide skin care is regulated as a cosmetic and isn't affected by any of this," she says.
Topical versus injectable: the difference matters
Peptides are short chains of amino acids that work as messengers in skin care—so the choice depends on which messages your skin cells need to receive. "Signal peptides like palmitoyl pentapeptide-4 tell fibroblasts to make more collagen. Carrier peptides like copper tripeptide-1 (GHK-Cu) deliver copper, a cofactor for wound healing and matrix repair. Neurotransmitter-inhibiting peptides like acetyl hexapeptide-8 (Argireline) modestly soften expression lines," Erickson explains. "So saying a product contains peptides is like saying a salad contains vegetables. You need to know what the peptides are and what they do."
Topical peptides act locally in the skin's upper layers and must penetrate the barrier, which makes formulation critical. Injectable peptides are a different category entirely. "They're delivered into the body, often act systemically, and many currently circulating online are not FDA-approved," says Foad. On oral options, she notes that collagen peptides are the most studied, with solid clinical data showing modest improvements in skin hydration and elasticity. Erickson adds that independently funded trials of oral collagen are far less flattering than the industry-funded ones.
Foad singles out injectable GHK-Cu as the peptide marketed most aggressively for skin right now—and advises against it. "Injectable GHK-Cu has never had clear FDA authorization for routine compounding, and we don't have strong human data on dosing, safety, or long-term outcomes for cosmetic use," she warns. Her alternative: "What I do recommend is using proven in-office treatments to drive collagen, such as microneedling, lasers, and biostimulatory fillers, and pairing them with topical copper peptides at home. Topicals have a strong track record, excellent tolerability, and zero needle risk."
The most famous injectable peptides right now are GLP-1 medications like semaglutide, which the FDA has approved for weight loss and diabetes—not skin.
The risks of the DIY injectable market
Erickson's biggest concern is what she calls "the DIY injectable crowd." "Grey-market vials labeled 'research use only' have no guarantee of purity, dose, or sterility. Injecting those near the face invites infections, abscesses, and granulomas," she says.
She is also watching Melanotan II, a tanning peptide that stimulates pigment cells, which the FDA is slated to review for compounding in early 2027. "There are published reports of changing moles and melanoma in users. A dermatologist cannot be casual about a compound designed to darken your moles. Loosening the rules on that one would be a real step backward for skin cancer prevention," says Erickson.
The products dermatologists recommend
Copper peptides, specifically GHK-Cu, top Foad's list for supporting collagen and elastin production, repair, firmness and texture. "I love Asterwood Copper Peptides Serum, which pairs GHK-Cu with hyaluronic acid for added hydration," she recommends. Matrixyl, or palmitoyl pentapeptide-4, has real clinical data behind its wrinkle-reducing benefits; The Ordinary Matrixyl 10 percent + HA and Olay Regenerist Micro-Sculpting Cream are affordable, targeted options. For expression lines, she points to The Ordinary Argireline Solution 10 percent, which delivers acetyl hexapeptide-8 at a meaningful concentration. "I strongly recommend choosing a peptide serum or cream you'll leave on the skin, rather than a cleanser, so the ingredients have time to work," Foad concludes.
Peptides are the supporting cast, not the star
Erickson stresses that the fundamentals of aging skin care have not changed: daily sunscreen, a retinoid if tolerated, and a healthy barrier. For women in perimenopause and menopause, she says the conversation should also include hormones, because estrogen loss drives much of the collagen decline people try to fix with peptides. "A peptide can nudge a fibroblast. It can't replace what the ovaries stopped sending."
Her bottom-line advice for shoppers: "Be curious, not credulous. Buy topical peptides from reputable brands. Be deeply skeptical of anything sold in a vial with 'not for human use' on the label. That warning is the one honest thing on it." With FDA reviews of GHK-Cu and Melanotan II coming in 2027, the regulatory story around injectable peptides—and the marketing around them—will keep evolving.
Original: monadermatology.com
More from Grace Kim
Show full bio
Correspondent covering media and advertising at Eurasian Beauty Journal.
36 articles
